BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 18538728)

  • 1. MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?
    Muntean AG; Hess JL
    Cancer Cell; 2008 Jun; 13(6):465-7. PubMed ID: 18538728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
    Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
    Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.
    Krivtsov AV; Twomey D; Feng Z; Stubbs MC; Wang Y; Faber J; Levine JE; Wang J; Hahn WC; Gilliland DG; Golub TR; Armstrong SA
    Nature; 2006 Aug; 442(7104):818-22. PubMed ID: 16862118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mll fusions generated by Cre-loxP-mediated de novo translocations can induce lineage reassignment in tumorigenesis.
    Drynan LF; Pannell R; Forster A; Chan NM; Cano F; Daser A; Rabbitts TH
    EMBO J; 2005 Sep; 24(17):3136-46. PubMed ID: 16096649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer biology: a game of subversion.
    Passegué E
    Nature; 2006 Aug; 442(7104):754-5. PubMed ID: 16915276
    [No Abstract]   [Full Text] [Related]  

  • 6. Searching for leukemia stem cells--not yet the end of the road?
    Jordan CT
    Cancer Cell; 2006 Oct; 10(4):253-4. PubMed ID: 17045202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of an interphase fluorescence in situ hybridization approach for the detection of MLL gene rearrangements and of the MLL/AF9 fusion in acute myeloid leukemia.
    Cavazzini F; Bardi A; Tammiso E; Ciccone M; Russo-Rossi A; Divona D; Lo Coco F; Hernandez JM; Wlodarska I; Hagemeijer A; Castoldi G; Cuneo A
    Haematologica; 2006 Mar; 91(3):381-5. PubMed ID: 16503549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
    Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation from committed progenitor to leukemia stem cells.
    Krivtsov AV; Feng Z; Armstrong SA
    Ann N Y Acad Sci; 2009 Sep; 1176():144-9. PubMed ID: 19796242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heritable genetic background alters survival and phenotype of Mll-AF9-induced leukemias.
    Young K; Loberg MA; Eudy E; Schwartz LS; Mujica KD; Trowbridge JJ
    Exp Hematol; 2020 Sep; 89():61-67.e3. PubMed ID: 32768438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells.
    Hotfilder M; Röttgers S; Rosemann A; Schrauder A; Schrappe M; Pieters R; Jürgens H; Harbott J; Vormoor J
    Cancer Res; 2005 Feb; 65(4):1442-9. PubMed ID: 15735032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel AF9 breakpoint in MLL-AF9-positive acute monoblastic leukemia.
    Alonso CN; Longo PL; Gallego MS; Medina A; Felice MS
    Pediatr Blood Cancer; 2008 Apr; 50(4):869-71. PubMed ID: 18000862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
    Chiarella E; Aloisio A; Scicchitano S; Todoerti K; Cosentino EG; Lico D; Neri A; Amodio N; Bond HM; Mesuraca M
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixed lineage leukemia: roles in human malignancies and potential therapy.
    Marschalek R
    FEBS J; 2010 Apr; 277(8):1822-31. PubMed ID: 20236311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.
    Huntly BJ; Shigematsu H; Deguchi K; Lee BH; Mizuno S; Duclos N; Rowan R; Amaral S; Curley D; Williams IR; Akashi K; Gilliland DG
    Cancer Cell; 2004 Dec; 6(6):587-96. PubMed ID: 15607963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLL-AF9 oncogene expression affects cell growth but not terminal differentiation and is downregulated during monocyte-macrophage maturation in AML-M5 THP-1 cells.
    Pession A; Martino V; Tonelli R; Beltramini C; Locatelli F; Biserni G; Franzoni M; Freccero F; Montemurro L; Pattacini L; Paolucci G
    Oncogene; 2003 Nov; 22(54):8671-6. PubMed ID: 14647461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of the two reciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL confer resistance to apoptosis, cell cycling capacity and growth transformation.
    Gaussmann A; Wenger T; Eberle I; Bursen A; Bracharz S; Herr I; Dingermann T; Marschalek R
    Oncogene; 2007 May; 26(23):3352-63. PubMed ID: 17130830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.
    Liu Q; Chen L; Atkinson JM; Claxton DF; Wang HG
    Cell Death Dis; 2016 Sep; 7(9):e2361. PubMed ID: 27607576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype.
    Santillan DA; Theisler CM; Ryan AS; Popovic R; Stuart T; Zhou MM; Alkan S; Zeleznik-Le NJ
    Cancer Res; 2006 Oct; 66(20):10032-9. PubMed ID: 17047066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
    Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.